



**ESSEX BIO-TECHNOLOGY LIMITED**

**億勝生物科技有限公司**

**(Stock Code: 1061)**

**The cellular growth factor project of Essex Bio-Technology Limited was honoured with the second prize of National Scientific and Technology Progress Award**

Hong Kong, 10 January 2019

Essex Bio-Technology Limited (“EssexBio” or the “Group”—Stock Code: 1061) is pleased to announce that Zhuhai Essex Bio-Pharmaceutical Company Limited, an indirectly wholly-owned subsidiary of the Group, was honoured with the second prize of National Scientific and Technology Progress Award, in the 2018 National Science and Technology Award Conference, in relation to the project of *Key Technical Breakthrough, Theory Innovation, and Industrialisation for Protein Drugs of Cellular Growth Factor in China*.

The National Science and Technology Award was established by the State Council and would be appraised once a year. According to the newly released Plan for Deepening the Reform of the Science and Technology Award System, it is stipulated that the total number of awards awarded by the Three National Awards shall not exceed 300 per year. The National Science and Technology Award includes the National Natural Science Award, the National Science and Technology Invention Award and the National Science and Technology Progress Award, which are commonly referred to as the Three National Awards. The 2018 National Science and Technology Award Conference was held in Beijing on January 8, 2019. In the Conference 278 projects and 7 experts were appraised and

elected, among which 32 awards were given to the Medicine and Healthcare projects including one first prize and 20 second prizes of the National Science and Technology Progress Award.

The awarded project of EssexBio was jointly researched and developed by Zhuhai Essex Bio-Pharmaceutical Company Limited, Wenzhou Medical University, Anhui Anke Biotechnology (Group) Co.,Ltd., and Guangzhou Jinan University Biopharmaceutical R&D Centre. Based on highly underserved clinical needs, the project created a pattern of drug development and clinical translation in a strategic alliance of “University-Enterprise-Hospital” , and provided the support on both theoretical and practical basis, to sustainable development of the recombinant protein drug in China.

The core technology of the project has been extensively used in the Group. In 1990, the Group established its R&D team, to start research and development of rb-bFGF (recombinant bovine basic fibroblast growth factor). In 1996, the Group set up a factory for the production of API (active pharmaceutical ingredients) and formulations. Currently the Group has five commercialised bio-pharmaceutical products, formulated with rb-bFGF, in China, out of which 3 are approved by National Medical Products Administration (“NMPA”) in China as Category I drugs. The products are being marketed & sold as Beifushu, Beifuji & Beifuxin, for treatment of ocular surface wounds and topical (skin) surface wounds respectively.

The Group is honoured and encouraged on being conferred the prestigious award and would like to extend its gratitude and appreciations to all stakeholders for their contributions. The Group will continue to leverage on its R&D platform of bFGF & know-how, along with other novel technologies in its quest for delivering first-in-class bio-pharmaceutical products in the field of Ophthalmology and Surgery (Surgical arena of topical surface wounds), Orthopaedics, Neurology and Oncology.

#### **About EssexBio**

Essex Bio-Technology Limited is a bio-pharmaceutical company, started in early 90's, a pioneer in bio-pharmaceutical industry in China, that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF, a basic fibroblast growth factor, with established mechanism of action in cellular proliferation, differentiation and migration.

The Company currently has five commercialised bio-pharmaceutical products, formulated with rb-bFGF, in China, out of which 3 are approved by National Medical Products Administration (“NMPA”) in China as

Category I drugs. The products are being marketed & sold as Beifushu, Beifuji & Beifuxin, for treatment of ocular surface wounds and topical (skin) surface wounds respectively. Beifuji is the first in the world to have obtained approval from NMPA for commercialisation in 1998.

In addition, the Group has three NMPA approved preservative-free, single-dose eye drops: Tobramycin, Levofloxacin and Sodium Hyaluronate, approved in April 2017, June 2018 and August 2018, respectively.

The Company focuses on two main therapeutics, Ophthalmology and Surgical arena of topical (skin) surface wounds, which primarily covers Dermatology, Stomatology and Obstetrics & Gynaecology, while selectively pursuing therapeutics in Neurology, Oncology and Orthopaedics. The Company maintains a pipeline of multi-project in R&D and on various stages of clinical programs, of which several projects involving growth factors and antibody and a handful of projects are on unit dose for Ophthalmic and Respiratory disease.

The Company's products and its 3rd party products are marketed and sold through more than 5,600 hospitals in China and are managed directly by its 42 regional sales offices with about 1,400 sales and marketing people. Its 3rd party products; notably are inclusive of Xalacom eye drops and Xalatan eye drops of Pfizer (for Ophthalmology), Iodized Lecithin Capsules (for Ophthalmology), Yi Xue An Granules (for Obstetrics & Gynaecology) and Carisolv Products (for Stomatology).

Zhixin Investor Relations Consultant issued this press release on behalf of **Essex Bio-Technology Limited**.

For further information, please contact:

Zhixin Investor Relations Consultant Limited

Ms. Tan Ronghua

Tel: +86 (755) 8323 9767

E-mail: [tanronghua@zhixincaijing.com](mailto:tanronghua@zhixincaijing.com)